X

Trial Profile

A Phase 1/2 HSV-2 vaccine study

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVx 201 (Primary)
Indications Herpes simplex virus type 2 infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

19 Aug 2022 New trial record
15 Aug 2022 According to a Rational Vaccines media release, company announced the launch of a clinical trial designed to determine the baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex virus type 2 (HSV-2). In addition to assessing the typical baseline characteristics of population, the purpose of this study is also to determine the acceptance of clinical trial procedures and understand the interest of the target patient population to participate in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com